TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture for Elevated Intraocular Pressure

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~patients of either gender; age 21 years and older; intraocular pressure equal/greater than 20mmHg, equal/less than 30mmHg; ability to comply with study protocol~Exclusion Criteria:~patients with secondary or closed-angle glaucoma; patients with a history of laser or other surgical treatment of glaucoma; patients displaying symptoms of depression, anxiety or psychosis

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary endometrial carcinoma meeting 1 of the following criteria:~  * Stage III or IV disease according to FIGO staging criteria~ * Recurrent disease that is considered incurable~* Measurable disease~  * A lesion within a previously irradiated field is acceptable as measurable disease only if there has been clear progression since completion of radiotherapy~PATIENT CHARACTERISTICS:~* GOG performance status 0-2~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 9 g/dL~* Creatinine \< 2.5 mg/dL OR creatinine clearance ≥ 60 mL/min~* ALT and AST ≤ 1.5 times upper limit of normal (ULN) (3 times ULN in the presence of liver metastases)~* Alkaline phosphatase ≤ 1.5 times ULN (3 times ULN in the presence of liver metastases)~* Total bilirubin ≤ 1.5 times ULN (3 times ULN in the presence of liver metastases)~* Not pregnant or nursing~* Left ventricular ejection fraction (LVEF) ≥ 50% by MUGA scan or ECHO~* No history of severe hypersensitivity reaction to doxorubicin hydrochloride liposome~* No other invasive malignancy (i.e., breast cancer) within the past 5 years except nonmelanoma skin cancer~* No cardiac disease, including any of the following:~  * Myocardial infarction within the past 6 months~ * NYHA class II-IV heart failure~ * Uncontrolled angina~ * Severe uncontrolled ventricular arrhythmias~ * Clinically significant pericardial disease~ * Acute ischemic or active conduction system abnormalities by ECHO~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy~* No prior cancer therapy that would contraindicate study treatment~* No concurrent investigational agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doxorubicin and carboplatin (Type: EXPERIMENTAL): Patients receive doxorubicin hydrochloride liposome IV over 1 hour on day 1 and carboplatin IV over 30 minutes on day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of SIMVASTATIN to Treat Chronic Rhinosinusitis After Failure of Optimal Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women aged between 18 and 65 years.~* Chronic rhinosinusitis with or without nasal polyposis requiring functional endoscopic surgery type of bilateral total ethmoidectomy older than six months~* Failure (clinical and endoscopic score \> 1 on a scale of 3) of conventional treatment after surgery followed by local treatment with corticosteroids and saline irrigation)~Exclusion Criteria:~* Cystic Fibrosis~* Primary immunodeficiencies or documented acquired~* Diabetes~* Taking anticoagulants or bleeding disorders~* Taking oral cortisone within 30 days prior to the inclusion~* Taking antibiotics within 30 days prior to the inclusion~* Sinus or nasal surgery in past six months~* Contraindication to statins (pregnancy or lactating; people consuming high quantities of alcohol (3 drinks/day or more), liver disease, severe renal failure, myopathy, hypersensitivity to statins, abnormally elevated transaminase coagulation)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- SIMVASTATIN 40mg (Type: EXPERIMENTAL): SIMVASTATIN tablet of 40mg once a day during 30 days. Single arm with pre and post treament assessment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: S9927 Radiation Therapy After Surgery, Chemotherapy, and/or Hormone Therapy in Stage II Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage II adenocarcinoma of the breast (T1-2, N1, M0)~  * Primary tumor no greater than 5 cm~ * At least 1 but no more than 3 positive axillary lymph nodes~ * Nodes cannot be positive solely by cytokeratin staining~ * No apocrine, adenocystic, or squamous cell carcinomas or sarcomas of the breast~ * No bilateral breast cancer~ * No active local regional disease~* Must have undergone a modified radical mastectomy with a level I and II with or without a level III axillary dissection (at least 10 nodes examined) within the past 8 months~  * Surgical margins negative for invasive and noninvasive ductal carcinoma~ * No gross extracapsular disease or residual disease in the axilla~ * Microscopic extracapsular extension allowed~* No mastectomy after local failure following lumpectomy~* Must have received adjuvant chemotherapy and/or hormonal therapy after mastectomy~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 21 and over~Sex:~* Female~Menopausal status:~* Pre- or post-menopausal~Performance status:~* Zubrod 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No serious medical or psychiatric illness that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior trastuzumab (Herceptin)~Chemotherapy:~* See Disease Characteristics~* No more than 6 weeks since prior adjuvant chemotherapy~* No other prior chemotherapy~* Concurrent adjuvant chemotherapy allowed~Endocrine therapy:~* See Disease Characteristics~* Concurrent adjuvant hormonal therapy allowed~Radiotherapy:~* No prior chest wall or nodal radiotherapy~Surgery:~* See Disease Characteristics~* Breast reconstruction allowed~Other:~* Concurrent registration on another adjuvant chemotherapy or hormonal therapy study is allowed

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- surgery (Type: ACTIVE_COMPARATOR): surgery followed by observation
- surgery followed by RT (Type: EXPERIMENTAL): Surgery followed by radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does IV Ondansetron Prevent Pruritus After Intrathecal Morphine in Pediatric Patients?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 3-17 years~* weight \</= 100kg~* scheduled for urologic or orthopedic procedure necessitating intrathecal morphine~* ability to use verbal or pictorial pain assessment tools and techniques~* informed consent and (if applicable) assent~Exclusion Criteria:~* Inability to use verbal or pictorial pain scoring scales~* hypersensitivity to selective 5-HT receptor antagonists~* diagnosed congenital long QT syndrome~* severe hepatic impairment~* pregnancy or nursing mothers

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Ondansetron IV (Type: EXPERIMENTAL): Ondansetron IV X1 intraoperatively (0.1 mg/kg in 5 mLs) Ondansetron IV X 4 (Q 6 hrs for 24 hrs) (0.1 mg/kg in 5 mLs)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo Comparator: This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively X1 as well as IV every 6 hrs for 24 hours postoperatively. (X4)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must be aged 18-65~* Must be at least 15% below ideal body weight~Exclusion Criteria:~* Allergy to quetiapine~* Diagnosis of schizophrenia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Goal Directed Haemodynamic Treatment for Patients With Proximal Femoral Fracture

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (men and women) age ≥ 70 years~* Patients´ scheduled for operation of proximal femoral fracture during office hours~* Patient who have a witnessed or written informed consent~Exclusion Criteria:~Any of the following is regarded as a criterion for exclusion from the study:~* Concomitant medication with Lithium~* Known allergy (or hypersensitivity) to Lithium, or components of the medical device~* Weight ≤ 40 kg~* Other conditions or symptoms preventing the subject from entering the study, according to investigators judgment~* Life expectancy less than 6 months and/or pathological fractures~* Not possible to insert arterial line.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Routine fluid treatment (Type: ACTIVE_COMPARATOR): Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h and additionally as needed Voluven at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension
- Goal directed haemodynamic treatment (Type: EXPERIMENTAL): Goal directed haemodynamic treatment Dobutamine 0.2-10 μg/kg/min Buffered Glucose 25 mg/ml 1ml/kg/h Ringer's Acetate 2 ml/kg/h Voluven 3 ml/kg as fluid challenge at the attending anaesthetist's discretion Phenylephrine 50 μg for correction of hypotension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Age greater than or equal to 18 years old and less than or equal to 65 years~ 2. Loa loa microfilaremia \>500 MF/mL and \<2500 MF/mL at screening visit.~ 3. Subject has the capacity to understand the potential risks and benefits and consents to protocol indicated blood draws and follow up visits.~EXCLUSION CRITERIA:~1. Women under 45 years of age, or over 45 years of age with a menstrual period in the preceding 12 months.~2. Currently breastfeeding~3. Currently taking daily medications~4. Known chronic medical conditions, including but not limited to diabetes, renal failure, liver disease, seizure disorder, HIV, malignancy, psychiatric disorder, or any conditions which within the investigators judgement are deemed to be clinically significant.~5. W. bancrofti serologic positivity against Wb123~6. O. volvulus serologic positivity against Ov16~7. HIV by history or clinical signs of HIV/AIDS (e.g. oral thrush, oral/skin lesions of Kaposi s sarcoma, etc.)~8. Any of the following lab abnormalities: Creatinine \>1.5, Platelets \<100,000/mL, Hemoglobin \<12g/dL, alanine aminotransferase or aspartate aminotransferase \>60 U/L, total bilirubin \>1.7mg/dL, absolute neutrophil count equal to or less than 1500/mm(3).~9. Any condition that, in the opinion of the PI, may substantially increase the risk of participation, including any contraindication to imatinib.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects given vitamin placebo
- Imatinib 200mg (Type: EXPERIMENTAL): Subjects given a single dose of imatinib 200mg PO
- Imatinib 400mg (Type: EXPERIMENTAL): Subjects given a single dose of imatinib 400mg PO
- Imatinib 600mg (Type: EXPERIMENTAL): Subjects given a single dose of imatinib 600mg PO

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Must have a diagnosis of RRMS as defined by the revised consensus definition for pediatric MS~* Must have an EDSS score between 0.0 and 5.0.~* Must have a body weight of ≥30 kg~* Must have experienced ≥1 relapse in the 12 months prior to randomization (Day 1), or must have evidence of asymptomatic disease activity seen on MRI in the 6 months prior to randomization, or ≥2 relapses in the 24 months prior to randomization (Day 1). Relapse is defined as the occurrence of a clinical demyelination event regardless of whether the event is a first or subsequent demyelinating event.~Key Exclusion Criteria:~* Participants having primary progressive, secondary progressive, or progressive RMS.~* Disorders mimicking MS, such as other demyelinating disorders, systemic autoimmune disorders, metabolic disorders, and infectious disorders.~* History of clinically significant cardiovascular, pulmonary, GI, hepatic, renal, endocrinologic, hematologic, immunologic, metabolic, dermatologic, growth, developmental, psychiatric (including depression), neurologic (other than MS), and/or other major disease and/or laboratory abnormality indicative thereof, that would preclude participation in a clinical study~* Occurrence of an MS relapse within the 30 days prior to randomization (Day 1) and/or the subject has not stabilized from a previous relapse prior to randomization~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Dimethyl Fumarate 240 mg (Type: EXPERIMENTAL): Participants will receive dimethyl fumarate 240 milligrams (mg) capsule twice daily (BID) orally and placebo subcutaneous (SC) injection every 2 weeks for up to 96 weeks (2 years).
- Peginterferon Beta-1a 125 µg (Type: EXPERIMENTAL): Participants will receive peginterferon beta-1a 125 micrograms (µg) SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years).
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo SC injection every 2 weeks and placebo capsule BID orally for up to 96 weeks (2 years)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Clinical Effectiveness of the Delta Xtend Reverse Total Shoulder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects, aged less than 85 years inclusive.~* Subjects who have cuff tear arthropathy, osteoarthritis with cuff deficiency, rheumatoid arthritis, post traumatic injury, or a need for revision surgery of a failed anatomic prosthesis in the left or right shoulder, which requires (total) shoulder arthroplasty.~* Subjects with radiographic evidence of sufficient bone stock to seat and support the Delta XtendÔ Reverse Total Shoulder System.~* Subjects who in the opinion of the Clinical Investigator are considered suitable for treatment with the Delta Xtend Reverse Total Shoulder System.~* Patients with a life expectancy of greater than 12 months.~* Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained.~* Subjects who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, co-operate with the investigational procedures and are willing to return to the hospital for all the required post-operative follow-ups.~Exclusion Criteria:~* Male and female subjects aged 86 years or older.~* Subjects with complete deltoid muscle palsy in the target joint as determined by clinical evaluation.~* Subjects with active local or systemic infection or with a history of general or local infections in the target joint over the past 12 months.~* Subjects with severe deformities, or tumours, that would impair fixation or proper positioning of the implant.~* Subjects with no significant muscle, nerve or vascular disease.~* Subjects with a pathology that, in the opinion of the Clinical Investigator, will adversely affect healing.~* Known allergic reactions to implant materials (e.g. bone cement, metal, polyethylene) implant corrosion or implant wear debris.~* Subjects with a known history of poor compliance to medical treatment.~* Subjects who, in the opinion of the Clinical Investigator, have an existing condition that would compromise their participation and follow-up in this clinical investigation.~* Women who are pregnant.~* Subjects who are known drug or alcohol abusers or with psychological disorders that could affect follow-up care or treatment outcomes.~* Subjects who have participated in a clinical investigation with an investigational product in the last month.~* Subjects who are currently involved in any injury litigation claims.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Delta Xtend Reverse Total Shoulder (Type: OTHER): Orthopaedic implant for total shoulder replacement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Multimodality Image-guided System for Peripheral Lung Cancer Diagnosis and Therapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult (age ≥ 18 years) subjects with peripheral lung lesions that are \<1.5 cm in size who are planning to undergo percutaneous image guided lung biopsy as part of their routine medical care.~* 2. Ability to understand and willingness to sign Informed Consent Document (ICD)~Exclusion Criteria:~* Age less than 18 years.~* Pregnant or nursing females.~* Known allergy to iodine or intravenous contrast agent.~* Known allergy or anaphylactic reaction to indocyanine green (ICG).~* Patients with renal dysfunction (GFR \<60) or patients on dialysis~* Patients with liver dysfunction: total bilirubin \> 2.5 mg/dl; albumin \< 2.5 mg/dl; alanine aminotransferase (ALT), aspartate aminotransferase (AST) \> 5 times upper limits of normal~* Uncorrectable coagulopathy prohibiting biopsy. (INR \> 1.5 and/ or platelets \< 50,000)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 2 (Type: EXPERIMENTAL): During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the the lung biopsy.
- Group 3 (Type: EXPERIMENTAL): During standard of care lung biopsy, the doctor will use the MIMIG system to help guide the needle for the lung biopsy. An intravenous (IV) needle placed in the vein to give indocyanine green (IC-Green). Fiber Optic camera will be used to view tissue before biopsy via insertion catheter.
- Group 1 (Type: NO_INTERVENTION): Control Group consists of twelve patients who have undergone biopsy of a peripheral lung lesion by using repetitive CT-guidance. Review of medical records only, no further intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues